Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

Background The association between obesity and outcomes in patients receiving programmed death-1/programmed death ligand-1 (PD-L1) checkpoint inhibitors has already been confirmed in pre-treated non-small cell lung cancer (NSCLC) patients, regardless of PD-L1 tumor expression.Methods We present the...

Full description

Saved in:
Bibliographic Details
Main Authors: Danilo Rocco, Alex Friedlaender, Alfredo Addeo, Diego Signorelli, Alessio Cortellini, Sebastiano Buti, Raffaele Giusti, Marcello Tiseo, Pietro Di Marino, Michele De Tursi, Federica Zoratto, Marco Russano, Marco Filetti, Francesca Rastelli, Rita Chiari, Biagio Ricciuti, Alain Gelibter, Mario Alberto Occhipinti, Giampiero Porzio, Corrado Ficorella, Emilio Bria, Alessandro Morabito, Giuseppe L Banna, Joachim GJV Aerts, Fausto Barbieri, Diego L Cortinovis, Maria R Migliorino, Annamaria Catino, Francesco Passiglia, Mariangela Torniai, Carlo Genova, Francesca Mazzoni, Vincenzo Di Noia, Alessandro Inno, Giovanni Mansueto, Francesco Grossi, Pamela Pizzutilo, Fabrizio Citarella, Luca Cantini, Giada Targato, Olga Nigro, Miriam G Ferrara, Simona Scodes, Lorenza Landi, Giorgia Guaitoli, Luigi Della Gravara, Fabrizio Tabbò, Serena Ricciardi, Alessandro De Toma, Fausto Petrelli
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e001403.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/8/2/e001403.full

Similar Items